Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vaxart to Present at World Vaccine and Immunotherapy Congress West Coast 2018
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 28, 2018-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Sean Tucker , Ph.D., chief scientific officer, will
View HTML
Toggle Summary Vaxart Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Start of Norovirus Vaccine Trials Delayed to 1H 2019 Due to Manufacturing Issue SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 9, 2018-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today
View HTML
Toggle Summary New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart’s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity
Vaxart oral tablet vaccine provided 39% reduction in flu illness compared to 27% for Fluzone ® Strong β7 + plasmablasts response in Vaxart vaccinees was highly correlated with protection SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 4, 2018-- Vaxart, Inc.
View HTML
Toggle Summary Vaxart Announces Second Quarter 2018 Financial Results and Corporate Update
SOUTH SAN FRANCISCO --(BUSINESS WIRE)--Aug. 9, 2018-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the second quarter ended June 30, 2018 and provided a
View HTML
Toggle Summary Vaxart Announces Publication of the Phase 1 Results of its Oral Norovirus Tablet Vaccine in Journal of Clinical Investigation Insight
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 12, 2018-- Vaxart, Inc. (Nasdaq:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced publication of the comprehensive results of the previously
View HTML
Toggle Summary Oral RSV Vaccine - Preclinical Data Published in Vaccine
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 27, 2018-- Vaxart, Inc. (Nasdaq:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced publication of the preclinical results of its oral
View HTML
Toggle Summary Vaxart Reports Topline Results from Phase 2 Trial of Teslexivir™ for the Treatment of Condyloma
Safety and tolerability profile comparable to placebo Primary efficacy endpoint not achieved - Positive trend in two important subgroups SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 4, 2018-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are
View HTML
Toggle Summary Vaxart to Present at the Jefferies 2018 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 1, 2018-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Wouter Latour , M.D., president and chief executive
View HTML
Toggle Summary Vaxart to Present at ASM Microbe 2018
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 31, 2018-- Vaxart, Inc. (NASDAQ:VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo , Ph.D., lead scientist of Vaxart , will
View HTML
Toggle Summary Vaxart Announces First Quarter 2018 Financial Results and Corporate Update
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 15, 2018-- Vaxart, Inc. (Nasdaq:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the first quarter ended March 31,
View HTML
Toggle Summary Vaxart Appoints Dr. David Taylor as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 1, 2018-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of David Taylor , M.D., as Chief Medical Officer. Dr.
View HTML
Toggle Summary Vaxart Announces $5 Million Inavir® Revenue Milestone
2017 Net Sales of Inavir ® in Japan Exceeded ¥20 Billion, Triggering USD $5 Million Milestone Payment SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 20, 2018-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than
View HTML
Toggle Summary Vaxart Appoints Brant Biehn as Senior Vice President, Commercial Operations
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 19, 2018-- Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of Brant Biehn as Senior Vice President,
View HTML
Toggle Summary Vaxart to Present at Two Upcoming Medical Meetings
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 16, 2018-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that new preclinical data on its intranasal Chikungunya
View HTML
Toggle Summary Vaxart Announces Oral Presentation of Clinical Data from Oral Influenza Vaccine Program at the World Vaccine Congress
SOUTH SAN FRANCISCO, Calif., April 2, 2018 — Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that the complete clinical dataset from the Phase 2 Challenge Study of its H1
View HTML

Log In

Create an account